PGEN
Precigen, Inc.
NASDAQ · USHealthcareBiotechnology
$5.07+2.42%
Price as of Jul 20, 2026
PGEN valuation
Precigen, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- 69.17x
- P/E 2028E
- 13.25x
- P/S forward
- 24.43x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 89.33x
- Price / sales
- 57.21x
- Price / cash flow
- -15.67x
Enterprise value
- Enterprise value
- $1.8B
- EV / sales
- 58.54x
- EV / EBITDA
- -9.48x
- EV / EBIT
- -19.70x
- Market cap
- $1.8B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.